AbbVie Acquires Apogee Therapeutics for USD 10.9 Billion to Boost Immunology Pipeline sheeba farhat23 Jun 2026 11:24 PM ISTBengaluru: AbbVie said on Monday it would buy biotech Apogee Therapeutics for USD 10.9 billion, in its largest buyout in more than five years as it...
Sanofi's Rare Lung Disease Drug Outperforms Standard Therapy in Head-to-Head Trial sheeba farhat19 May 2026 9:58 PM ISTLondon: French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a ‌key...
FDA extends approval of Dupilumab for Young Children with Chronic Spontaneous Urticaria Dr. Kamal Kant Kohli24 April 2026 9:15 PM ISTThe FDA has expanded approval of dupilumab to include children aged 2 to 11 years with chronic spontaneous urticaria who continue to have symptoms...
FDA Approves First Treatment for Allergic Fungal Rhinosinusitis Dr. Kamal Kant Kohli26 Feb 2026 8:30 PM ISTThe FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS), marking the first approved therapy for this...
Sanofi Replaces CEO Paul Hudson Amid Vaccine Headwinds, Names Belen Garijo Successor sheeba farhat13 Feb 2026 2:00 PM ISTNew Delhi: French drugmaker Sanofi abruptly ousted its CEO Paul Hudson on Thursday, underscoring rising pressure from U.S. vaccine headwinds and a...
Sanofi-Regeneron Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Ruchika Sharma23 Dec 2025 11:30 AM ISTParis: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing...
Sanofi-Regeneron Dupixent approved in EU for chronic spontaneous urticaria Ruchika Sharma26 Nov 2025 1:00 PM ISTParis: Sanofi has announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic...
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid Dr. Kamal Kant Kohli22 Jun 2025 8:45 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous pemphigoid, a rare blistering...
Sanofi Dupixent gets USFDA nod for bullous pemphigoid treatment in adults Ruchika Sharma20 Jun 2025 12:15 PM ISTParis: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adult patients...
Sanofi-Regeneron Dupixent data reinforce use in atopic dermatitis patients with skin of color Ruchika Sharma9 Jun 2025 1:12 PM ISTParis: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent (dupilumab) in adults and...
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade Dr. Kamal Kant Kohli21 April 2025 9:15 PM ISTThe US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged...
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria Ruchika Sharma19 April 2025 1:15 PM ISTParis: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the...
